Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 05/24 09:48:58 am
1440.165 GBp   +0.15%
05/20DJChina Drug Deal Will Slash Prices of Top-Selling Treatments by Up..
05/19 INNOVIVA : GSK presents new data from Breo® Ellipta® SUMMIT study in..
05/18 GLAXOSMITHKLINE : GSK Presents Efficacy Data for Anoro(R) Ellipta(R)..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2012 | 02:29pm CEST

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

Stephen Rea

+44 (0) 20 8047 5502

(London)

Sarah Spencer

+44 (0) 20 8047 5502

(London)

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664

(Philadelphia)

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+ 44 (0) 20 8047 5503

(London)

James Dodwell

+ 44 (0) 20 8047 2406

(London)

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on GLAXOSMITHKLINE PLC
05/20DJChina Drug Deal Will Slash Prices of Top-Selling Treatments by Up to 67%
05/19 INNOVIVA : GSK presents new data from Breo® Ellipta® SUMMIT study in patients wi..
05/18 GLAXOSMITHKLINE : GSK Presents Efficacy Data for Anoro(R) Ellipta(R) in COPD Pat..
05/18 GLAXOSMITHKLINE : GSK Present New Data From Breo(R) Ellipta(R) SUMMIT Study in P..
05/18 GLAXOSMITHKLINE : Glaxo Presents Positive Breo Ellipta, Anoro Ellipta Data
05/18 GLAXOSMITHKLINE : How much should patients know about pharma payments to doctors..
05/18DJNovartis Says Drug-Unit Chief To Leave Firm -- WSJ
05/18 NOVARTIS : SPLITS BUSINESS Phama boss set to quit amid restructuring
05/17DJNovartis to Split Pharmaceuticals Division into Two -- Update
05/17DJNovartis to Split Drug Division
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials